Insmed reported $201.64M in Equity Capital and Reserves for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Acelrx Pharmaceuticals ACRX:US $ -27.31M 28.44M
Alexion Pharmaceuticals ALXN:US $ 12416.8M 765.6M
Alimera Sciences ALIM:US $ -11.96M 3.98M
Arena Pharmaceuticals ARNA:US $ 1085.99M 5.52M
Biomarin Pharmaceutical BMRN:US $ 4241.57M 79.56M
Cytokinetics CYTK:US $ 67.85M 45.54M
Dynavax Technologies DVAX:US $ 99.76M 41.07M
Flexion Therapeutics FLXN:US $ -38867000 22.21M
Gilead Sciences GILD:US $ 19710M 758M
Heron Therapeutics HRTX:US $ 196.22M 40.27M
Insmed INSM:US $ 201.64M 74.25M
Mirati Therapeutics MRTX:US $ 1259.41M 101.38M
Novartis NVS:US $ 54042M 3519M
Regeneron Pharmaceuticals REGN:US $ 11977M 951.7M
Sarepta Therapeutics SRPT:US $ 535.45M 226.31M
Seattle Genetics SGEN:US $ 3391.27M 33.35M
Ultragenyx Pharmaceutical RARE:US $ 1054.58M 99.79M
Vertex Pharmaceuticals VRTX:US $ 9196.4M 216.14M